Natixis Advisors’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-13,505
| Closed | -$297K | – | 1650 |
|
|
2025
Q1 | $297K | Buy |
+13,505
| New | +$318K | ﹤0.01% | 1551 |
|
|
2024
Q1 | – | Sell |
-10,537
| Closed | -$458K | – | 1553 |
|
|
2023
Q4 | $458K | Buy |
+10,537
| New | +$415K | ﹤0.01% | 1404 |
|
|
2023
Q2 | – | Sell |
-32,570
| Closed | -$1.87M | – | 1489 |
|
|
2023
Q1 | $1.87M | Buy |
32,570
+6,141
| +23% | +$346K | 0.01% | 971 |
|
|
2022
Q4 | $1.48M | Buy |
26,429
+7,450
| +39% | +$379K | 0.01% | 1027 |
|
|
2022
Q3 | $804K | Buy |
18,979
+2,514
| +15% | +$129K | ﹤0.01% | 1163 |
|
|
2022
Q2 | $890K | Sell |
16,465
-1,223
| -7% | -$73.4K | ﹤0.01% | 1151 |
|
|
2022
Q1 | $1.14M | Buy |
17,688
+135
| +0.8% | +$8.89K | ﹤0.01% | 1094 |
|
|
2021
Q4 | $1.18M | Buy |
17,553
+1,639
| +10% | +$111K | ﹤0.01% | 1088 |
|
|
2021
Q3 | $1.09M | Buy |
15,914
+1,314
| +9% | +$92.8K | ﹤0.01% | 1071 |
|
|
2021
Q2 | $996K | Buy |
14,600
+95
| +0.7% | +$6.72K | ﹤0.01% | 1096 |
|
|
2021
Q1 | $1M | Buy |
14,505
+746
| +5% | +$50.5K | 0.01% | 1059 |
|
|
2020
Q4 | $893K | Buy |
13,759
+2,892
| +27% | +$156K | 0.01% | 1032 |
|
|
2020
Q3 | $513K | Sell |
10,867
-70,898
| -87% | -$3.37M | ﹤0.01% | 1047 |
|
|
2020
Q2 | $3.84M | Sell |
81,765
-12,299
| -13% | -$605K | 0.03% | 595 |
|
|
2020
Q1 | $4.2M | Buy |
94,064
+22,518
| +31% | +$1.18M | 0.03% | 503 |
|
|
2019
Q4 | $4.17M | Buy |
71,546
+2,175
| +3% | +$129K | 0.03% | 598 |
|
|
2019
Q3 | $4.17M | Buy |
69,371
+2,162
| +3% | +$129K | 0.03% | 536 |
|
|
2019
Q2 | $3.75M | Sell |
67,209
-18,094
| -21% | -$932K | 0.03% | 564 |
|
|
2019
Q1 | $4.75M | Buy |
85,303
+16,907
| +25% | +$861K | 0.04% | 462 |
|
|
2018
Q4 | $3.08M | Buy |
68,396
+34,245
| +100% | +$1.88M | 0.03% | 548 |
|
|
2018
Q3 | $2.25M | Buy |
34,151
+2,400
| +8% | +$149K | 0.02% | 737 |
|
|
2018
Q2 | $2.04M | Sell |
31,751
-16,358
| -34% | -$1.01M | 0.02% | 754 |
|
|
2018
Q1 | $2.66M | Sell |
48,109
-1,083
| -2% | -$56.8K | 0.03% | 673 |
|
|
2017
Q4 | $2.35M | Sell |
49,192
-26,667
| -35% | -$1.31M | 0.02% | 672 |
|
|
2017
Q3 | $3.83M | Sell |
75,859
-3,797
| -5% | -$195K | 0.04% | 512 |
|
|
2017
Q2 | $4.34M | Buy |
79,656
+3,355
| +4% | +$160K | 0.05% | 477 |
|
|
2017
Q1 | $3.21M | Buy |
76,301
+20,607
| +37% | +$881K | 0.04% | 570 |
|
|
2016
Q4 | $1.19M | Sell |
55,694
-980
| -2% | -$39.8K | 0.01% | 793 |
|
|
2016
Q3 | $2.34M | Sell |
56,674
-63,340
| -53% | -$2.65M | 0.03% | 613 |
|
|
2016
Q2 | $4.79M | Buy |
120,014
+8,840
| +8% | +$318K | 0.07% | 380 |
|
|
2016
Q1 | $3.74M | Sell |
111,174
-33,986
| -23% | -$1.06M | 0.06% | 435 |
|
|
2015
Q4 | $4.92M | Sell |
145,160
-159,850
| -52% | -$5M | 0.08% | 323 |
|
|
2015
Q3 | $9.08M | Sell |
305,010
-31,823
| -9% | -$995K | 0.16% | 156 |
|
|
2015
Q2 | $8.39M | Sell |
336,833
-44
| -0% | -$1.17K | 0.14% | 190 |
|
|
2015
Q1 | $8.49M | Sell |
336,877
-5,490
| -2% | -$130K | 0.15% | 179 |
|
|
2014
Q4 | $7.59M | Buy |
342,367
+10,334
| +3% | +$210K | 0.14% | 188 |
|
|
2014
Q3 | $6.74M | Sell |
332,033
-316,926
| -49% | -$6.31M | 0.14% | 209 |
|
|
2014
Q2 | $12.5M | Buy |
648,959
+24,411
| +4% | +$455K | 0.18% | 156 |
|
|
2014
Q1 | $11.7M | Sell |
624,548
-16,256
| -3% | -$314K | 0.18% | 170 |
|
|
2013
Q4 | $12.5M | Buy |
640,804
+20,063
| +3% | +$368K | 0.2% | 129 |
|
|
2013
Q3 | $10.2M | Sell |
620,741
-15,148
| -2% | -$243K | 0.19% | 161 |
|
|
2013
Q2 | $9.52M | Buy |
+635,889
| New | +$9.32M | 0.19% | 165 |
|
Other funds holding IART
RCMNY
PCMI
Natixis Advisors's IART Position: Q2 2025 in Review
Natixis Advisors sold out of Integra LifeSciences (IART) in Q2 2025, closing a stake of 13,505 shares — an estimated $297K sold.
Natixis Advisors first reported a position in IART in Q2 2013 and held it in 42 quarters. The position peaked at $12.5M in Q4 2013. 208 funds tracked by Wall St. Rank hold IART as of Q2 2025.
- Natixis Advisors reported no remaining Integra LifeSciences position as of Q2 2025 after selling out during the quarter.
- Natixis Advisors sold 13,505 Integra LifeSciences shares in Q2 2025, an estimated $297K.
- Natixis Advisors first reported a position in Integra LifeSciences in Q2 2013 and held it in 42 quarters.
- Natixis Advisors's Integra LifeSciences position peaked at $12.5M in Q4 2013.
- 208 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2025.
Based on Natixis Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.